AC
ARRY

Avestar Capital’s Array Biopharma Inc ARRY Stock Holding History

Avestar Capital’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-520
Closed -$12K – 1016
2019
Q1 		$12K Buy
520
+190
+58% +$3.96K 0.01% 462
2018
Q4 		$4K Buy
+330
New +$5.01K ﹤0.01% 575

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Avestar Capital's ARRY Position: Q2 2019 in Review

Avestar Capital sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 520 shares — an estimated $12K sold.

Avestar Capital first reported a position in ARRY in Q4 2018 and held it in 2 quarters. The position peaked at $12K in Q1 2019. 318 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • Avestar Capital reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • Avestar Capital sold 520 Array Biopharma Inc shares in Q2 2019, an estimated $12K.
  • Avestar Capital first reported a position in Array Biopharma Inc in Q4 2018 and held it in 2 quarters.
  • Avestar Capital's Array Biopharma Inc position peaked at $12K in Q1 2019.
  • 318 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Avestar Capital's 13F filing for Q2 2019, filed 6 Aug 2019.